NO315146B1 - Oral enterisk belagt formulering, fremgangsmåte for dens fremstilling, og anvendelse derav - Google Patents

Oral enterisk belagt formulering, fremgangsmåte for dens fremstilling, og anvendelse derav Download PDF

Info

Publication number
NO315146B1
NO315146B1 NO19960067A NO960067A NO315146B1 NO 315146 B1 NO315146 B1 NO 315146B1 NO 19960067 A NO19960067 A NO 19960067A NO 960067 A NO960067 A NO 960067A NO 315146 B1 NO315146 B1 NO 315146B1
Authority
NO
Norway
Prior art keywords
omeprazole
formulation according
enteric
core material
coated
Prior art date
Application number
NO19960067A
Other languages
English (en)
Norwegian (no)
Other versions
NO960067D0 (no
NO960067L (no
Inventor
Inga Siv Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO315146(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO960067D0 publication Critical patent/NO960067D0/no
Publication of NO960067L publication Critical patent/NO960067L/no
Publication of NO315146B1 publication Critical patent/NO315146B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19960067A 1993-07-09 1996-01-05 Oral enterisk belagt formulering, fremgangsmåte for dens fremstilling, og anvendelse derav NO315146B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation
PCT/SE1994/000681 WO1995001783A1 (en) 1993-07-09 1994-07-08 New pharmaceutical formulation

Publications (3)

Publication Number Publication Date
NO960067D0 NO960067D0 (no) 1996-01-05
NO960067L NO960067L (no) 1996-01-05
NO315146B1 true NO315146B1 (no) 2003-07-21

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960067A NO315146B1 (no) 1993-07-09 1996-01-05 Oral enterisk belagt formulering, fremgangsmåte for dens fremstilling, og anvendelse derav

Country Status (39)

Country Link
US (1) US5690960A (cs)
EP (1) EP0706378B1 (cs)
JP (1) JP3665334B2 (cs)
KR (1) KR100350203B1 (cs)
CN (1) CN1126946A (cs)
AT (1) ATE231719T1 (cs)
AU (1) AU681686B2 (cs)
BR (1) BR9406941A (cs)
CA (1) CA2166483C (cs)
CZ (1) CZ290323B6 (cs)
DE (1) DE69432076T2 (cs)
DK (1) DK0706378T3 (cs)
DZ (1) DZ1794A1 (cs)
EE (1) EE03148B1 (cs)
EG (1) EG22373A (cs)
ES (1) ES2191682T3 (cs)
FI (1) FI114008B (cs)
HR (1) HRP940386B1 (cs)
HU (1) HU226779B1 (cs)
IL (1) IL110189A0 (cs)
IS (1) IS2034B (cs)
LV (1) LV13140B (cs)
MA (1) MA23258A1 (cs)
MX (1) MX9405219A (cs)
MY (1) MY128809A (cs)
NO (1) NO315146B1 (cs)
NZ (1) NZ268694A (cs)
PL (1) PL175210B1 (cs)
RU (1) RU2138254C9 (cs)
SA (1) SA94150057B1 (cs)
SE (1) SE9302395D0 (cs)
SG (1) SG52365A1 (cs)
SI (1) SI0706378T1 (cs)
SK (1) SK281105B6 (cs)
TN (1) TNSN94078A1 (cs)
UA (1) UA43342C2 (cs)
WO (1) WO1995001783A1 (cs)
YU (1) YU49199B (cs)
ZA (1) ZA944934B (cs)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FI970058A0 (fi) * 1994-07-08 1997-01-07 Astra Ab Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
PT723436E (pt) * 1994-07-08 2002-02-28 Astrazeneca Ab Forma de dosagem em comprimidos com unidades multiplas
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
PL332503A1 (en) * 1996-09-24 1999-09-13 Lilly Co Eli Coated particles containing preparation
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CA2298823C (en) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
NZ511169A (en) 1998-11-18 2003-06-30 Astrazeneca Ab Process for making substituted sulphinyl heterocycles containing an imidazole moiety
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
EP1244430A4 (en) * 1999-03-29 2004-01-14 Wyeth Corp COATING SYSTEM
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
BR0110926A (pt) * 2000-05-15 2004-02-17 Ranbaxy Lab Ltd Novas formas amorfas de sais de omeprazol e processo de preparação dos mesmos
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
RU2284189C2 (ru) * 2001-08-27 2006-09-27 Киова Кемикал Индастри Ко., Лтд. Антацидная и слабительная таблетка
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
WO2003032953A1 (en) 2001-10-17 2003-04-24 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
AU2003209534A1 (en) * 2002-03-08 2003-09-22 Bakulesh Mafatlal Khamar The method of treating tuberculosis
EP1524967B1 (en) * 2002-08-02 2008-03-12 Ratiopharm GmbH Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
RU2261021C2 (ru) * 2002-12-24 2005-09-27 Ромашев Николай Анатольевич Способ окрашивания твердой прессованной композиции
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) * 2003-03-28 2004-09-29 Acme Drugs S R L Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
RU2257890C2 (ru) * 2003-10-06 2005-08-10 Марио Атилио Лос Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US8871273B2 (en) * 2005-02-25 2014-10-28 Takeda Pharmaceutical Company Limited Method for producing granules
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2068837A2 (en) * 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
PT2379063E (pt) 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
US9532739B2 (en) 2011-06-14 2017-01-03 Gravitas Medical, Inc. Methods and apparatus for guiding medical care based on detected gastric function
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
JPWO2021153525A1 (cs) 2020-01-27 2021-08-05
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
WO2022014601A1 (ja) * 2020-07-13 2022-01-20 キリンホールディングス株式会社 フィルムコーティング錠剤
CN113350313B (zh) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 一种艾司奥美拉唑镁延释制剂及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation

Also Published As

Publication number Publication date
CA2166483C (en) 1997-09-16
CA2166483A1 (en) 1995-01-19
PL175210B1 (pl) 1998-11-30
FI114008B (fi) 2004-07-30
EG22373A (en) 2002-12-31
IL110189A0 (en) 1994-10-21
IS4187A (is) 1995-01-10
HUT75306A (en) 1997-05-28
DZ1794A1 (fr) 2002-02-17
EE03148B1 (et) 1999-02-15
BR9406941A (pt) 1996-09-10
SI0706378T1 (en) 2003-06-30
WO1995001783A1 (en) 1995-01-19
MX9405219A (es) 1995-01-31
DK0706378T3 (da) 2003-05-05
CN1126946A (zh) 1996-07-17
HK1008299A1 (en) 1999-05-07
PL312441A1 (en) 1996-04-29
DE69432076D1 (de) 2003-03-06
ATE231719T1 (de) 2003-02-15
SK281105B6 (sk) 2000-12-11
FI960102A0 (fi) 1996-01-09
DE69432076T2 (de) 2003-10-16
FI960102L (fi) 1996-01-09
SA94150057B1 (ar) 2006-10-03
SE9302395D0 (sv) 1993-07-09
HU226779B1 (en) 2009-10-28
HRP940386A2 (en) 1997-02-28
EP0706378B1 (en) 2003-01-29
KR100350203B1 (ko) 2002-12-28
HU9503874D0 (en) 1996-02-28
RU2138254C9 (ru) 2009-09-27
EP0706378A1 (en) 1996-04-17
US5690960A (en) 1997-11-25
MA23258A1 (fr) 1995-04-01
SK2196A3 (en) 1997-04-09
MY128809A (en) 2007-02-28
AU7198294A (en) 1995-02-06
ES2191682T3 (es) 2003-09-16
CZ7096A3 (en) 1996-06-12
JPH08512316A (ja) 1996-12-24
NO960067D0 (no) 1996-01-05
CZ290323B6 (cs) 2002-07-17
RU2138254C1 (ru) 1999-09-27
LV13140B (en) 2004-08-20
IS2034B (is) 2005-08-15
ZA944934B (en) 1995-02-20
NZ268694A (en) 1997-05-26
AU681686B2 (en) 1997-09-04
NO960067L (no) 1996-01-05
YU49199B (sh) 2004-09-03
JP3665334B2 (ja) 2005-06-29
UA43342C2 (uk) 2001-12-17
SG52365A1 (en) 1998-09-28
TNSN94078A1 (fr) 1995-04-25
HRP940386B1 (en) 2003-10-31
YU43794A (sh) 1997-07-31

Similar Documents

Publication Publication Date Title
NO315146B1 (no) Oral enterisk belagt formulering, fremgangsmåte for dens fremstilling, og anvendelse derav
DK169987B1 (da) Oralt indgiveligt farmaceutisk præparat, der som aktiv bestanddel indeholder en syrelabil forbindelse eller et alkalisalt heraf, samt en fremgangsmåde til fremstilling af præparatet
DK169988B1 (da) Oralt indgiveligt farmaceutisk præparat, der som aktiv bestanddel indeholder omeprazol eller et alkalisalt heraf, samt en fremgangsmåde til fremstilling af præparatet
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
NO328100B1 (no) Farmasoytisk formulering av omeprazol
PL181265B1 (pl) Doustny preparat omeprazolu i sposób jego wytwarzania
EP2293782B1 (en) Stable benzimidazole formulation
RU2173995C2 (ru) Лекарственный препарат для перорального введения, содержащий магниевую соль омепразола
HK1008299B (en) New pharmaceutical formulation
JPH10504288A (ja) オメプラゾールのマグネシウム塩を含有する新規な経口医薬処方物
HK1156209B (en) Stable benzimidazole formulation

Legal Events

Date Code Title Description
MK1K Patent expired